A new trading day began on Monday, with Axsome Therapeutics Inc (NASDAQ: AXSM) stock price down -2.21% from the previous day of trading, before settling in for the closing price of $86.70. AXSM’s price has ranged from $64.11 to $105.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 88.16% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -3.05%. With a float of $39.61 million, this company’s outstanding shares have now reached $48.44 million.
In an organization with 545 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.55%, operating margin of -90.84%, and the pretax margin is -91.97%.
Axsome Therapeutics Inc (AXSM) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Axsome Therapeutics Inc is 18.26%, while institutional ownership is 79.16%. The most recent insider transaction that took place on Sep 11 ’24, was worth 1,005,871. In this transaction Director of this company sold 11,016 shares at a rate of $91.31, taking the stock ownership to the 10,002 shares. Before that another transaction happened on Sep 11 ’24, when Company’s Director proposed sale 11,016 for $91.31, making the entire transaction worth $1,005,843.
Axsome Therapeutics Inc (AXSM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.05% per share during the next fiscal year.
Axsome Therapeutics Inc (NASDAQ: AXSM) Trading Performance Indicators
Here are Axsome Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.54, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -1.51 in one year’s time.
Technical Analysis of Axsome Therapeutics Inc (AXSM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.13 million. That was better than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 32.55%. Additionally, its Average True Range was 4.26.
During the past 100 days, Axsome Therapeutics Inc’s (AXSM) raw stochastic average was set at 31.32%, which indicates a significant decrease from 37.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.46% in the past 14 days, which was lower than the 36.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $93.22, while its 200-day Moving Average is $84.15. However, in the short run, Axsome Therapeutics Inc’s stock first resistance to watch stands at $87.99. Second resistance stands at $91.19. The third major resistance level sits at $97.41. If the price goes on to break the first support level at $78.57, it is likely to go to the next support level at $72.35. The third support level lies at $69.15 if the price breaches the second support level.
Axsome Therapeutics Inc (NASDAQ: AXSM) Key Stats
With a market capitalization of 4.11 billion, the company has a total of 48,462K Shares Outstanding. Currently, annual sales are 270,600 K while annual income is -239,240 K. The company’s previous quarter sales were 104,760 K while its latest quarter income was -64,600 K.
